Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination bowel preparation regimen consists of polyethylene glycol electrolyte lavage solution (PEG-ELS) and bisacodyl, a stimulant laxative. It was specifically evaluated by researchers at the University of Oklahoma in a randomized controlled trial (NCT01141374) to determine if adding bisacodyl to a split-dose PEG-ELS regimen would improve bowel cleansing quality in diabetic patients undergoing colonoscopy. PEG-ELS functions as an osmotic laxative, utilizing a non-absorbable solution to induce liquid stools and cleanse the colon without causing significant fluid or electrolyte shifts. Bisacodyl acts directly on the colonic mucosa to stimulate peristalsis. The specific protocol studied involved 10 mg of oral bisacodyl followed by 4 liters of PEG-ELS administered in a split-dose format. Although intended to enhance preparation in a difficult-to-cleanse population, the study found no statistically significant improvement with the addition of bisacodyl compared to split-dose PEG-ELS alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyethylene glycol electrolyte lavage solution + bisacodyl.